A single bout of vigorous intensity exercise enhances the efficacy of rituximab against human chronic lymphocytic leukaemia B-cells ex vivo
(2024)
Journal Article
Collier-Bain, H. D., Emery, A., Causer, A. J., Brown, F. F., Oliver, R., Dutton, D., Crowe, J., Augustine, D., Graby, J., Leach, S., Eddy, R., Rothschild-Rodriguez, D., Gray, J. C., Cragg, M. S., Cleary, K. L., Moore, S., Murray, J., Turner, J. E., & Campbell, J. P. (2024). A single bout of vigorous intensity exercise enhances the efficacy of rituximab against human chronic lymphocytic leukaemia B-cells ex vivo. Brain, Behavior, and Immunity, 118, 468-479. https://doi.org/10.1016/j.bbi.2024.03.023
Chronic lymphocytic leukaemia (CLL) is characterised by the clonal proliferation and accumulation of mature B-cells and is often treated with rituximab, an anti-CD20 monoclonal antibody immunotherapy. Rituximab often fails to induce stringent disease...
Read More about A single bout of vigorous intensity exercise enhances the efficacy of rituximab against human chronic lymphocytic leukaemia B-cells ex vivo.